WisdomTree Cloud Computing Fund (NASDAQ: WCLD)

에 대한 최신 뉴스 WisdomTree Cloud Computing Fund (NASDAQ:WCLD)

Technology

Financial Services

Healthcare

Communication Services

Other

The Fund employs a passive management – or indexing – investment approach designed to track the performance of the Index. The Fund generally uses a representative sampling strategy to achieve its investment objective, meaning it generally will invest in a sample of the securities in the Index whose risk, return and other characteristics resemble the risk, return and other characteristics of the Index as a whole. Under normal circumstances, at least 80 percent of the Funds total assets (exclusive of collateral held from securities lending) will be invested in component securities of the Index and investments that have economic characteristics that are substantially identical to the economic characteristics of such component securities.

Block, Inc

Ncino, Inc.

Q2 Holdings Inc (information Technology)

Docusign Inc

Okta Inc.

Squarespace Inc

Ringcentral Inc Cl A

Paypal Holding Inc

Blackline Inc (information Technology)

Toast, Inc.

WisdomTree Cloud Computing Fund

Equities

News

Markets

Tech

General

ARKW

CLOU

GOOG

GOOGL

IONQ

MSFT

NVDA

QBTS

QTUM

QUBT

RGTI

WCLD

양자 컴퓨팅은 인공지능(AI)이 디지털 환경을 혁신적으로 변화시킨 것과 마찬가지로 산업을 혁신할 게임 체인저 기술로 떠오르고 있다. 2025년을 향해 나아가면서 전문가들은 양자 컴퓨팅이 기술의 다음 주요 경계가 되어 엄청난 계산 능력을 열어주고 암호화, 약물 발견 및 최적화와 같은 분야에서의 혁신을 이끌 것이라고 예측하고 있다.

양자 컴퓨팅: 새로운 AI? 2025년에 빠르게 확장되는 시장 및 상위 주식 살펴보기

Stifel analyst Stephen Gengaro maintains Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) with a Buy and lowers the price target from $60 to $59.

Price Target

Analyst Ratings

Stifel Maintains Buy on Schlumberger, Lowers Price Target to $59

Barclays analyst Ramsey El-Assal maintains Paychex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) with a Equal-Weight and raises the price target from $135 to $140.

PAYX

Barclays Maintains Equal-Weight on Paychex, Raises Price Target to $140

Shares of Rumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) rose sharply in today's pre-market trading after the company announced it has entered into a definitive agreement for a strategic <a href="https://www.benzinga.com/24/12/42634166/rumble-stock-soars-on-775-million-investment-from-tether-what-to-know">investment of $775 million from Tether</a>.
Tether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>) has agreed to purchase 103.33 million shares of Rumble Class A Common Stock at a price per share of $7.50, totaling $775 million in gross proceeds to Rumble.
Rumble shares jumped 43.3% to $10.31 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Reliance Global Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>) gained 234% to $4.01 in pre-market trading.</li>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) gained 88.6% to $3.32 in pre-market trading. Phio Pharmaceuticals, last week, announced a $1.15 million registered direct offering priced at-the-market under Nasdaq rules.</li>
<li>Edible Garden AG Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) climbed 82.3% to $0.4334 in pre-market trading after surging 63% on Friday. Edible Garden recently announced it experienced a 51% year-over-year increase in its preliminary Thanksgiving period sales.</li>
<li>JIADE Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) gained 60.9% to $0.8530 in pre-market trading. JIADE received Nasdaq notification letter regarding minimum bid price deficiency.</li>
<li>American Battery Technology Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABAT#NASDAQ">ABAT</a>) rose 44.1% to $1.60 in pre-market trading. On Friday, American Battery Technology priced its $5 million registered direct offering of 5 million shares at $1.00 per share.</li>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) gained 30.9% to $3.60 in pre-market trading after jumping more than 36% on Friday.</li>
<li>Brenmiller Energy Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNRG#NASDAQ">BNRG</a>) rose 28.8% to $0.9700 in pre-market trading after the company was awarded ISO/IEC 27001:2022 certification.</li>
<li>Honda Motor Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) gained 18% to $28.19 in pre-market trading. Honda Motor and Nissan Motor Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSANY#OTC">NSANY</a>) have started talks for a potential merger.</li>
<li>Kodiak Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) rose 14.9% to $9.94 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares tumbled 28.9% to $0.0531 in pre-market trading after jumping 14% on Friday. Conduit Pharmaceuticals recently announced it entered an agreement with Sarborg to leverage AI and its cybernetics platform to evaluate key deliverables across multiple areas of operations.</li>
<li>Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) declined 25.7% to $0.6759 in pre-market trading after jumping around 101% on Friday.</li>
<li>Onfolio Holdings, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONFO#NASDAQ">ONFO</a>) fell 24.4% to $1.21 in pre-market trading. Onfolio Holdings announced a quarterly preferred stock cash dividend of 75 cents per share.</li>
<li>iLearningEngines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AILE#NASDAQ">AILE</a>) shares fell 24.3% to $0.6703 in pre-market trading after declining 9% on Friday.</li>
<li>ConnectM Technology Solutions Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTM#NASDAQ">CNTM</a>) shares dipped 20% to $0.83 in pre-market trading after falling 8% on Friday. ConnectM Technology Solutions, last week, announced a year-over-year increase in third-quarter revenue results.</li>
<li>TPI Composites, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) fell 19.2% to $1.94 in today's pre-market trading after jumping 97% on Friday.</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) dipped 17.8% to $0.2293 in pre-market trading after jumping 64% on Friday. Aptose Biosciences, last week, announced it was granted an extension to provide compliance evidence for a continued Nasdaq listing.</li>
<li>Core Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLB#NYSE">CLB</a>) fell 11% to $15.00 in pre-market trading.</li>
<li>Astria Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>) shares fell 10.8% to $8.53 in pre-market trading.</li>
<li>SIGA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) fell 8.5% to $5.41 in pre-market trading.</li>
</ul>
Now Read This: &lt;a href=&#8221;https://www.benzinga.com/news/earnings/24/04/38307448/investor-sentiment-decreases-further-s-p-500-falls-for-fourth-straight-session&#8221;&gt;&lt;em&gt; Investor Sentiment Decreases Further, S&amp;P 500 Falls For Fourth Straight Session&lt;/em&gt;&lt;/a&gt;

Earnings

Pre-Market Outlook

Movers

Trading Ideas

$USDT

ABAT

AILE

APTO

ATXS

BNRG

CNTM

EDBL

HSDT

JDZG

LAES

NSANY

ONFO

PHIO

RELI

SIGA

TPIC

Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket

Stifel analyst Steven Wieczynski maintains Carnival (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) with a Buy and raises the price target from $32 to $34.

Stifel Maintains Buy on Carnival, Raises Price Target to $34

CleanSpark Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>), America's Bitcoin Miner&#xAE; (the "Company"), today announced it has achieved and exceeded the previously announced year-end target of 37 EH/s of operating hashrate.
&nbsp;
The Company's newest data centers in Tennessee and Wyoming were energized last week. This is part of a multistage energization process that will continue into the next quarter. The added hashrate from these sites paired with site expansion, and ongoing fleet upgrades, has allowed the Company to exceed 2024 YE guidance and deliver 37.5 EH/s of operating hashrate. Fleet efficiency has reached 17.7 J/Th and is expected to continue to improve as the Company continues its strategic growth plans. The Company expects its operating leverage to continue to increase as it proceeds with its next phase of growth to 50 EH/s, which is fully funded and expected in the first half of 2025. This growth is expected to be achieved through a mix of greenfield infrastructure development, organic growth via existing site expansion, and strategic M&amp;A, all funded with a portion of the proceeds of the Company's most recent offering. The current portfolio of data centers includes locations in Georgia, Wyoming, Tennessee, Mississippi, and New York. &nbsp;&nbsp;

CLSK

CleanSpark Expands Data Centers, Surpasses 2024 Bitcoin Mining Target with 37.5 EH/s Hashrate, Aims for 50 EH/s in Early 2025

Truist Securities analyst Srikripa Devarakonda maintains Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) with a Buy and lowers the price target from $100 to $43.

KROS

Truist Securities Maintains Buy on Keros Therapeutics, Lowers Price Target to $43

The Company has received approval to begin enrollment of the Phase 1b clinical trial in Australia
Phase 1b clinical trial will assess safety and tolerability along with biomarkers during three months of dosing with GT-02287 in people diagnosed with Parkinson's disease
Phase 1b clinical trial follows successful Phase 1 study in which GT-02287 was safe and well tolerated while demonstrating GCase target engagement

GANX

Gain Therapeutics Initiated Phase 1b Clinical Trial Of Lead Candidate GT-02287 In People With GBA1 And Idiopathic Parkinson's Disease

Barclays analyst Carter Gould maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Overweight and raises the price target from $160 to $165.

NBIX

Barclays Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $165

NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) ("NewGen" or the "Company") today announced that both parties involved in the previously announced reverse merger with European Wellness Investment Holdings Limited ("EWIHL") have appointed legal counsel to prepare the Share Purchase Agreement (the "SPA"). Additionally, by mutual consent, the signing date for the SPA has been extended from January 27, 2025, to February 28, 2025. This extension will allow both parties sufficient time to complete the necessary due diligence, finalize the terms of the agreement, and ensure compliance with all relevant NASDAQ requirements for reverse mergers.
This significant step follows the Company's&nbsp;prior announcement of a binding term sheet on December 11, 2024, which marked a pivotal moment in the Company's strategic partnership with EWIHL. This collaboration aims to leverage synergies between both companies to enhance service delivery and expand market reach in the healthcare sector.

NIVF

NewGenIvf Extends Reverse Merger Deadline to Finalize Agreement with EWIHL

Raymond James analyst Buck Horne upgrades Weyerhaeuser (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) from Market Perform to Outperform and announces $32 price target.

Upgrades

Raymond James Upgrades Weyerhaeuser to Outperform, Announces $32 Price Target

QuickLogic Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUIK#NASDAQ">QUIK</a>), a developer of embedded FPGA (eFPGA) Hard IP, ruggedized FPGAs, and endpoint AI solutions, announced today it has been awarded a $6.575 million contract. This funding will support the continued development and demonstration of Strategic Radiation Hardened (SRH) high reliability Field Programmable Gate Array (FPGA) technology. The initiative aims to meet current and future Department of Defense (DoD) strategic and space system requirements.

QUIK

QuickLogic Secures $6.6M Contract to Advance Radiation-Hardened FPGA Tech for DoD

RUM: 53% &#x7C; <a href="https://www.benzinga.com//node/42631159">Rumble shares are trading higher after the company announced it has entered into a definitive agreement for a strategic investment of $775 million from Tether.</a>
&nbsp;
TRAW: 212% &#x7C; <a href="https://www.benzinga.com//node/42643986">Traws Pharma Advances One-Dose Bird Flu Treatment with Results</a>
&nbsp;
RAPT: 94% &#x7C; <a href="https://www.benzinga.com//node/42644215">RAPT Therapeutics To Raise $150M in Private Placement to Advance Drug Pipeline</a>

RAPT

TRAW

Market-Moving News for December 23rd

Raymond James analyst Buck Horne upgrades PotlatchDeltic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCH#NASDAQ">PCH</a>) from Market Perform to Outperform and announces $45 price target.

Raymond James Upgrades PotlatchDeltic to Outperform, Announces $45 Price Target

Alliance Global Partners analyst Aaron Grey initiates coverage on Worksport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) with a Buy rating and announces Price Target of $2.

Initiation

WKSP

Alliance Global Partners Initiates Coverage On Worksport with Buy Rating, Announces Price Target of $2

Algorhythm Holdings, Inc. ("Algorhythm" or the "Company") (NASDAQ: RIME) – an AI technology and consumer electronics holding company, announced it will pause new capital raising activities for the next six months. In light of the Company's current cash position, combined with a comprehensive assessment of the current market environment and our business operations, our management team has decided to suspend seeking out any new financing plans for the next six months. During this period, the Company will not seek new investments including transactions like an "At-the-Market" (ATM) offering or usage of the Company's Shelf registration statement.
Additionally, the Company intends to seek the approval of its stockholders at its upcoming annual meeting of stockholders in January 2025, to implement a reverse stock split of its outstanding common stock to regain compliance with The Nasdaq Stock Market ("Nasdaq") minimum bid requirement.

Stock Split

RIME

Algorhythm Pauses Capital Raising, Plans Reverse Stock Split for Nasdaq Compliance

Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) ("Psyence Biomed" or the "Company") today announced that it has received notice from the Nasdaq Hearings panel that the Company has regained compliance with all applicable Nasdaq continued listing requirements.
As previously announced, Psyence Biomed requested to be transferred from The Nasdaq Global Market to The Nasdaq Capital Market, effective November 15, 2024. As a result of this transfer, the Company regained compliance with listing rules 5550(a)(5), the $1.0 million minimum market value of publicly held shares requirement, and 5550(b)(1), the $2.5 million minimum stockholders' equity requirement.
Additionally, the Company obtained shareholder approval during its Annual General Meeting on November 12, 2024 to effect a 75-for-1 share consolidation. This share consolidation, which went into effect on November 26, 2024, was intended to address Nasdaq's listing rule 5550(a)(2), the $1 minimum bid price requirement. As the Company's shares have traded above $1 for the subsequent 18 trading days following the share consolidation, the minimum bid price requirement has been formally satisfied.

Government

Regulations

Psyence Biomed Regains Nasdaq Compliance After Share Consolidation

Piper Sandler analyst Frank Schiraldi maintains Pathward Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASH#NASDAQ">CASH</a>) with a Overweight and raises the price target from $82 to $94.

CASH

Piper Sandler Maintains Overweight on Pathward Financial, Raises Price Target to $94

Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for aficamten, a next-in-class cardiac myosin inhibitor, for the treatment of obstructive hypertrophic cardiomyopathy (HCM). The MAA will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP).

CYTK

Cytokinetics' Heart Drug Aficamten Gains EMA Validation for Review

Barclays analyst Lauren Lieberman maintains Lamb Weston Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) with a Overweight and lowers the price target from $87 to $69.

Barclays Maintains Overweight on Lamb Weston Hldgs, Lowers Price Target to $69

Lennox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>), a leading provider of innovative climate control solutions, announced today its inclusion in the S&amp;P 500 Index, effective prior to the opening of trading. This milestone recognizes the company's sustained growth, innovation, and dedication to delivering advanced HVACR products that prioritize comfort and efficiency.
Widely recognized as the best single gauge of the U.S. large-cap market, the S&amp;P 500 measures the performance of 500 of the leading companies spanning all sectors of the U.S stock market. Inclusion in the index is determined by factors such as market capitalization, financial performance, and overall contribution to the economy, underscoring the success of Lennox in delivering value to shareholders and driving innovation.

Lennox Joins S&P 500, Highlighting Growth and Innovation in HVACR

The 1-Minute Market Report - November 17, 2024

Back To Business

Why The Election Rally Could Continue

The Enduring Advantage

Tech Concentration: A Global Phenomenon

ServiceNow: On A Possible Path To $1300+, But I'm Not Buying

Getting Active To Identify AI Winners

2025 Outlook: Building The Transformation

How Methodology Affects U.S. Technology Index Performance

Cloud ETFs are poised for growth due to rising AI-driven innovation, increasing public cloud spending, demand for data security, and businesses investing in flexible cloud solutions. Hence, investors could consider top cloud ETFs like the Global X Cloud Computing ETF (CLOU), WisdomTree Cloud Computing Fund (WCLD), and First Trust Cloud Computing ETF (SKYY). Keep reading... As businesses navigate challenges related to data ownership and security, cloud solutions are gaining traction, moving beyond traditional providers. Meanwhile, AI fuels innovation in cloud offerings, driving growth in both public and private cloud services and creating strong investment opportunities in cloud ETFs.
With a heightened focus on AI capabilities and data security, investors should consider top cloud ETFs, such as Global X Cloud Computing ETF Global X Cloud Computing ETF (<a href="https://stocknews.com/stock/CLOU/">CLOU</a>), WisdomTree Cloud Computing Fund (<a href="https://stocknews.com/stock/WCLD/">WCLD</a>), and First Trust Cloud Computing ETF (<a href="https://stocknews.com/stock/SKYY/">SKYY</a>).
Cloud providers are embracing retrieval-augmented generation (RAG) services to improve generative AI accuracy, driving innovation and competitiveness. As businesses invest in cloud technology for flexibility and growth, global public cloud spending is projected to rise 20.4% to <a href="https://www.gartner.com/en/newsroom/press-releases/2024-05-20-gartner-forecasts-worldwide-public-cloud-end-user-spending-to-surpass-675-billion-in-2024#:~:text=Worldwide%20end%2Duser%20spending%20on,(GenAI)%20and%20application%20modernization.">$675.40 billion in 2024</a>, while the overall cloud computing market is projected to reach <a href="https://cisomag.com/cloud-is-booming-and-it-is-going-to-get-better-in-2025-and-beyond/#:~:text=Cloud%20vendors%20will%20be%20working,at%20%24945%20million%20by%202025.">$945 billion by 2025</a>.
Hence, investors are increasingly turning to cloud computing ETFs, which focus on companies powering the digital revolution through infrastructure, software, and platforms. These ETFs present strong growth opportunities, benefiting from the sector's rapid expansion. Given this favorable backdrop, let's evaluate the three <a href="https://stocknews.com/category/technology-equities-etfs/">Technology Equities ETFs</a> picks, starting with number three.
ETF #3: Global X Cloud Computing ETF Global X Cloud Computing ETF (<a href="https://stocknews.com/stock/CLOU/">CLOU</a>)
CLOU is an exchange-traded fund launched and managed by Global X Management Company LLC. It invests in the public equity markets globally. The fund invests in stocks of companies in "SaaS," "PaaS," "IaaS," managed server storage, data center "REITs," and cloud and edge computing infrastructure, focusing on both growth and value stocks across diverse market capitalizations. It seeks to track the performance of the Indxx Global Cloud Computing Index using a full replication technique.
With $381.90 million in assets under management (AUM), CLOU's top holding Snowflake, Inc. (<a href="https://stocknews.com/stock/SNOW/">SNOW</a>) with a 4.81% weighting, followed by Shopify, Inc. (<a href="https://stocknews.com/stock/SHOP/">SHOP</a>), with a 4.79% weighting, and Twilio, Inc. (<a href="https://stocknews.com/stock/TWLO/">TWLO</a>), with 4.63%. It has a total of 38 holdings.
It has an expense ratio of 0.68%, higher than the category average of 0.58%. It currently has a <a href="https://www.investopedia.com/terms/n/nav.asp">NAV</a> of $25.12. CLOU's fund outflows were $13.93 million over the past month.
CLOU has gained 27.2% over the past three months and 32.1% over the past six months to close the last trading session at $25.38.
CLOU's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this promising outlook. The ETF's overall A rating equates to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
CLOU has an A grade for Buy &amp; Hold and Trade and a B for Peer. Of the 119 ETFs in the A-rated <a href="https://stocknews.com/category/technology-equities-etfs/">Technology Equities ETFs</a> group, it is ranked #40. <a href="https://stocknews.com/stock/CLOU/">Click here</a> to access all of CLOU's POWR Ratings.
ETF #2: WisdomTree Cloud Computing Fund (<a href="https://stocknews.com/stock/WCLD/">WCLD</a>)
WCLD is an exchange-traded fund launched by WisdomTree, Inc. The fund is co-managed by Mellon Investments Corporation and WisdomTree Asset Management, Inc. The fund invests in global public equity markets, targeting stocks of companies in the cloud computing sectors. It focuses on both growth and value stocks across various market capitalizations and includes socially conscious companies promoting environmental responsibility. WCLD seeks to track the performance of the BVP Nasdaq Emerging Cloud Index using a representative sampling technique.
With $533.50 million in AUM, the fund has a total of 65 holdings. WCLD's top holding is TWLO with a 2.24% weighting, followed by Asana, Inc. (<a href="https://stocknews.com/stock/ASAN/">ASAN</a>), with a 2.22% weighting, and Atlassian Corp. (<a href="https://stocknews.com/stock/TEAM/">TEAM</a>) with 2.19%.
WCLD has an expense ratio of 0.45%, lower than the category average of 0.58%. It currently has a NAV of $39.92. Its fund inflows came in at $20.36 million over the past month.
WCLD has gained 34.4% over the past six months and 30.3% over the past three months to close the last trading session at $40.64.
WCLD's strong outlook is reflected in its POWR Ratings. The ETF has an overall rating of A, translating to a Strong Buy in our proprietary rating system.
It has an A grade for Buy &amp; Hold and Trade. It is ranked #35 in the same group. To access all the POWR Ratings for WCLD, <a href="https://stocknews.com/stock/WCLD/">click here</a>.
ETF #1: First Trust Cloud Computing ETF (<a href="https://stocknews.com/stock/SKYY/">SKYY</a>)
SKYY is an exchange-traded fund launched and managed by First Trust Advisors LP. The fund invests in public equity markets, targeting companies in information technology, software, IT and internet services, infrastructure, data management, storage, hardware, and platforms for software creation via virtualization or middleware delivered online. It invests in both growth and value stocks across diversified market capitalizations and seeks to track the performance of the ISE CTA Cloud Computing Index using a full replication technique.
With $3.85 billion in AUM, the fund has a total of 64 holdings. SKYY's top holding is AppLovin Corp. (<a href="https://stocknews.com/stock/APP/">APP</a>), with a 5.27% weighting, followed by Amazon.com, Inc. (<a href="https://stocknews.com/stock/AMZN/">AMZN</a>), with a 3.84% weighting, and Arista Networks, Inc. (<a href="https://stocknews.com/stock/ANET/">ANET</a>) with 3.84%.
SKYY has an expense ratio of 0.60%, higher than the category average of 0.58%. It currently has a NAV of $125.38. Its fund outflows came in at $110.84 million over the past month.
SKYY has gained 45% year-to-date and 46.5% over the past year to close the last trading session at $127.16.
SKYY's strong outlook is reflected in its POWR Ratings. The ETF has an overall rating of A, translating to a Strong Buy in our proprietary rating system.
It has an A grade for Buy &amp; Hold and Trade. It is ranked #13 in the Technology Equities ETFs group. To access all the POWR Ratings for SKYY, <a href="https://stocknews.com/stock/SKYY/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
SKYY shares were trading at $126.25 per share on Tuesday afternoon, down $0.91 (-0.72%). Year-to-date, SKYY has gained 44.01%, versus a 28.06% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/skyy-wcld-clou-3-cloud-etfs-poised-for-growth-in-2024/>3 Cloud ETFs Poised for Growth in 2024</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Comments

WisdomTree Cloud Computing Fund

뉴스

에 대한 최신 뉴스 WisdomTree Cloud Computing Fund (NASDAQ:WCLD)

월요일, 12월 23, 2024

뉴스

파트너 / 기고자

벤징가 글로벌